BeiGene
BGNE
$148.85
Share price
-3.50%
Change (1 day)
-33.39%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $2.30 B
According to BeiGene 's latest financial reports the company's total liabilities are $2.30 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
BeiGene - Total liabilities on balance sheet (from 2014 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $2.26 B | 13.63% |
| 2022-12-31 | $1.99 B | -16.94% |
| 2021-12-31 | $2.40 B | 38.78% |
| 2020-12-31 | $1.73 B | 173.14% |
| 2019-12-31 | $0.63 B | 27.8% |
| 2018-12-31 | $0.49 B | 36.93% |
| 2017-12-31 | $0.36 B | 584.7% |
| 2016-12-31 | $52.9 M | 24.65% |
| 2015-12-31 | $42.44 M | 52.39% |
| 2014-12-31 | $27.85 M | -44.87% |
| 2013-12-31 | $50.52 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $0.72 B | -68.74% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $12.15 M | -99.47% | 🇺🇸 USA |